Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

603
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
603
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

6.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

606
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
606
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Day 100 Recovery of Absolute Number of Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cells Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas.

Biomedicines·2024
Same author

The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events.

Leukemia·2024
Same author

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.

Blood cancer journal·2024
Same author

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.

Nature communications·2024
Same author

Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy.

Blood advances·2024
Same author

Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy.

Transplantation and cellular therapy·2024

Related Experiment Video

Updated: Apr 22, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

6.9K

Brentuximab vedotin.

Stephen M Ansell1

  • 1Division of Hematology, Mayo Clinic, Rochester, MN.

Blood
|October 9, 2014
PubMed
Summary

Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, shows efficacy in CD30(+) lymphomas like Hodgkin lymphoma. It is approved for relapsed patients and is being studied in combination therapies.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Brentuximab vedotin targets the CD30 antigen, present on malignant cells in certain lymphomas.
  • It has demonstrated efficacy in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
  • Activity is also noted in other CD30-expressing lymphomas.

Purpose of the Study:

  • To summarize the efficacy and safety of brentuximab vedotin in CD30(+) malignancies.
  • To highlight its role as an approved treatment for relapsed diseases.
  • To discuss its combination with chemotherapy and ongoing clinical trials.

Main Methods:

  • Review of clinical trial data and published literature on brentuximab vedotin.
  • Analysis of efficacy and toxicity profiles in CD30(+) lymphoma patients.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Related Experiment Videos

Last Updated: Apr 22, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

6.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
  • Evaluation of its use as a single agent and in combination regimens.

    • Main Results:

    • Brentuximab vedotin is effective as a single agent for relapsed CD30(+) lymphomas.
    • The drug exhibits an acceptable toxicity profile.
    • Combination with chemotherapy is safe and under investigation in randomized trials.

    Conclusions:

    • Brentuximab vedotin is a valuable therapeutic option for patients with CD30(+) lymphomas.
    • Its established efficacy and safety support its use in relapsed settings.
    • Ongoing trials are exploring its potential in combination therapies for broader applications.